CEACAM5 and autoimmune polyendocrinopathy: The pooled analysis revealed that compared with the control group without APS, the treatment group with APS further reduced tumor marker levels: CEA (MD = −1.24, 95% CI: −1.58 to −0.89, p < 0.00001; heterogeneity: χ2 = 1.75, p = 0.19, I2 = 43%), SCC (MD = −1.18, 95% CI: -1.51 to −0.84, p < 0.00001; heterogeneity: χ2 = 1.33, p = 0.25, I2 = 25%), and CA125 (MD = −9.12, 95% CI: -18.22 to −0.01, p = 0.05; heterogeneity: χ2 = 10.68, p = 0.001, I2 = 91%) (Figure 6).